Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)

NCT00457899 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00457899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00457899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2007
Completion date
September 30, 2007
Enrollment
234 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

psychotic disorders, schizoaffective disorders, schizophrenia